Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068290 | 1.00 | CNR2 (0.47) | CNR2DDB1CRBNCNR1KDM1A | |
| SCHEMBL29348994 | 0.86 | CNR2 (0.59) | CNR2DDB1CRBNCNR1BRD4 | |
| SCHEMBL31068267 | 0.86 | CNR2 (0.59) | CNR2DDB1CRBNCNR1BRD4 | |
| SCHEMBL29348432 | 0.86 | DDB1 (0.39) | CNR2DDB1CRBNKDM1A | |
| SCHEMBL29348576 | 0.84 | DDB1 (0.38) | CNR2DDB1CRBNCNR1BRD4 | |
| SCHEMBL31068103 | 0.84 | DDB1 (0.38) | CNR2DDB1CRBNCNR1BRD4 | |
| SCHEMBL31068116 | 0.84 | CNR2 (0.47) | CNR2DDB1CRBNCNR1BRD4 | |
| SCHEMBL29348569 | 0.84 | DDB1 (0.39) | CNR2DDB1CRBNCNR1BRD4 | |
| SCHEMBL31068395 | 0.84 | DDB1 (0.39) | CNR2DDB1CRBNCNR1BRD4 | |
| SCHEMBL29348644 | 0.84 | CNR2 (0.47) | CNR2DDB1CRBNCNR1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |